Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
First Patient Dosed in Validive
®
Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021
Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery
WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2021 financial results and recent business updates.
Recent Business Updates
Validive
Monopar’s Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC) dosed its first patient in February 2021 and is actively recruiting patients and initiating ad
Share:
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:
H.C. Wainwright Global Life Sciences Conference
The Company s presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET
33 Annual Roth Conference, Healthcare
The Company s fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ET
Maxim s 2021 Emerging Growth Virtual Conference
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET | Source: Monopar Therapeutics Inc. Monopar Therapeutics Inc. Wilmette, Illinois, UNITED STATES
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the
European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer.
Using Monopar’s proprietary humanized uPAR antibody, MNPR-101, a multimodal imaging probe was developed and tested
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
Monopar Therapeutics Inc.February 9, 2021 GMT
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients, today announced the issuance of a patent covering composition of matter for MNPR-101 in Canada, adding to its existing protection in key markets around the world including the US, Europe and Japan.